Eli Lilly and Company (NYSE:LLY) Shares Purchased by McGlone Suttner Wealth Management Inc.

McGlone Suttner Wealth Management Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 13.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 727 shares of the company’s stock after acquiring an additional 87 shares during the period. McGlone Suttner Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of LLY. Capital Planning LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $262,000. CHURCHILL MANAGEMENT Corp acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company during the first quarter worth approximately $8,896,000. HighPoint Advisor Group LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $9,878,000. Finally, Leo Wealth LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $3,355,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $21.37 during mid-day trading on Friday, reaching $932.06. The company had a trading volume of 2,293,874 shares, compared to its average volume of 3,009,544. The company has a 50 day moving average of $910.84 and a 200-day moving average of $852.86. The firm has a market cap of $885.83 billion, a price-to-earnings ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LLY shares. Guggenheim lifted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Finally, Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $979.29.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.